0
Abstract: Slide Presentations |

COST-EFFECTIVENESS OF ROUTINE MEDIASTINOSCOPY WITH ENDOSCOPIC ULTRASOUND VERSUS POSITRON-EMISSION TOMOGRAPHY FOR THE STAGING OF NON-SMALL CELL LUNG CANCER FREE TO VIEW

Alex A. Balekian, MD*; Emmett Keeler, PhD; Brennan Spiegel, MD
Author and Funding Information

Univ of California, Los Angeles, Los Angeles, CA


Chest


Chest. 2009;136(4_MeetingAbstracts):40S. doi:10.1378/chest.136.4_MeetingAbstracts.40S-h
Text Size: A A A
Published online

Abstract

PURPOSE:  Non-small cell lung cancer (NSCLC) continues to have high incidence and mortality in the United States. Although surgical resection is theoretically curative for early stage disease, 5-year survival rates are not ideal, possibly due to inaccurate non-invasive staging.

METHODS:  Using TreeAge 8.0 software, we constructed a cost-effectiveness model from a payer standpoint. The existing literature was reviewed, including: recent ACCP guidelines for staging and treatment; meta-analyses for PET, mediastinoscopy, and endoscopic ultrasound (EUS); as well as Medicare reimbursement data for 2008. The model was constructed to include a non-invasive arm with routine PET followed by confirmatory mediastinoscopy in the event of a positive scan, or else lobectomy in the event of a negative scan. The invasive arm included routine mediastinoscopy plus EUS without routine PET, followed by lobectomy in the event of negative results.

RESULTS:  Using the base-case patient with biopsy-proven NSCLC and 30% probability of N2 disease, the invasive arm cost $7,443 for an average life expectancy (LE) of 4.392 years, while the non-invasive arm cost $8,062 for average LE of 4.394 years, yielding a cost difference of $619 per patient. The incremental cost-effectiveness ratio for routine PET was $309,500 for each life-year gained. A sensitivity analysis that varied costs by 50% and N2 prevalence from 0% to 60% consistently favored the invasive strategy.

CONCLUSION:  Routine mediastinoscopy plus EUS without the use of PET scan for the accurate staging of NSCLC is more cost-effective compared to a non-invasive approach. Most of the savings occur from eliminating unnecessary lung resections with post-surgical hospitalizations for occult mediastinal disease, as well as avoiding PET altogether in the entire cohort.

CLINICAL IMPLICATIONS:  The invasive staging approach saves resources, avoids unnecessary lobectomies, and results in equivalent life-year outcomes in a time when emerging technologies are being evaluated for comparative effectiveness.

DISCLOSURE:  Alex Balekian, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

2:30 PM - 3:30 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Intermetatarsal neuroma.
Academy of Ambulatory Foot and Ankle Surgery | 1/16/2004
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543